Goldman Sachs analyst Salveen Richter downgraded Intellia Therapeutics to Neutral from Buy with a price target of $32, down from $136. Intellia reported Q4 EPS and reiterated the near-term catalyst path for in vivo CRISPR gene-edited therapies, notes the analyst, who takes a more measured outlook on NTLA-2001’s opportunity in ATTR given competitive and commercial dynamics, along with “a quieter near-term catalyst path.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on NTLA:
- Intellia Therapeutics reports Q4 EPS ($1.46), consensus ($1.45)
- NTLA Upcoming Earnings Report: What to Expect?
- Intellia Therapeutics price target lowered to $24 from $38 at Baird
- Intellia Therapeutics, ReCode Therapeutics to develop genomic medicines for CF
- Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis
